Welcome to our dedicated page for CVS HEALTH SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health reported a Form 4 for a director reflecting routine equity compensation. On 11/20/2025, the director acquired 1,652.091 deferred stock units with each unit representing one share of CVS Health common stock. These units were issued for deferral of a semi-annual retainer under the company’s non-employee director compensation policy and were valued at the market price pursuant to the 2017 Incentive Compensation Plan. After this transaction, the director beneficially owned 40,053.5157 deferred stock units on a direct basis.
CVS Health Corp reported an insider equity transaction by a company director on a Form 4. On 11/20/2025, the director acquired 1,775 shares of CVS Health common stock, labeled as an acquisition, at a price of $76.04 per share. The filing explains that these shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, meaning they represent stock-based compensation rather than an open-market purchase. Following this transaction, the director directly owns 127,772 shares of CVS Health common stock.
CVS Health (CVS) reported a routine equity compensation transaction for a director. On 11/20/2025, a CVS director received 1,775 shares of common stock at a price of $76.04 per share. The shares were issued as payment of a semi-annual retainer under CVS Health's 2017 Incentive Compensation Plan, rather than a cash payment.
Following this grant, the director beneficially owns 13,659 shares of CVS Health common stock in direct ownership. This filing reflects standard board compensation in stock and does not describe any broader corporate or strategic change at CVS Health.
CVS Health (CVS) director Fernando Aguirre reported the receipt of company stock as part of his regular board compensation. On 11/20/2025, he acquired 1,800 shares of CVS Health common stock at a price of $76.04 per share. This stock was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, meaning it represents routine director compensation rather than an open-market purchase. Following this grant, Aguirre beneficially owns 40,950 shares of CVS Health common stock, held directly.
CVS Health Corporation announced a governance change at the top of its leadership structure. On November 20, 2025, the Board appointed President and Chief Executive Officer J. David Joyner to also serve as Chair of the Board, effective January 1, 2026. After this change takes effect, Michael F. Mahoney will continue as Lead Independent Director, and Roger N. Farah, currently Executive Chair, will remain on the Board as a director. The company also issued a press release describing this appointment, which is filed as an exhibit.
CVS Health Corp executive Amy Compton-Phillips filed an amended initial ownership report updating her holdings. The Form 3/A discloses 35 shares of CVS common stock held indirectly in a living trust for her benefit that were not previously reported due to a broker error.
CVS HEALTH Corp filed a Form 13F reporting institutional holdings. The filing lists a Form 13F Information Table Value Total of $102,889,417 across 3 holdings and shows 0 other included managers. The report was signed by Michael Motolo, Executive Director on 10-31-2025.
CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.
Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.
CVS Health Corporation furnished an update on its financial performance. The company announced results for the three months ended September 30, 2025, and made the related press release available as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.
CVS Health reported insider transactions by its EVP and Chief People Officer. The filing shows indirect purchases of common stock held by a trust for the benefit of the officer’s spouse. Reported trades: 35 shares at $56.47 on 09/09/2024, 10 shares at $62.24 on 10/02/2024, and 35 shares at $56.85 on 10/23/2024. The explanation notes the shares were bought at a broker’s discretion for a managed account and were not previously reported due to a broker error.